MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

Search

TransMedics Group Inc

Closed

Sector Healthcare

72.03 -4.73

Overview

Share price change

24h

Current

Min

71.61

Max

72.81

Key metrics

By Trading Economics

Income

-8M

4.2M

Sales

-5.5M

109M

P/E

Sector Avg

85.398

73.394

EPS

0.12

Profit margin

3.876

Employees

584

EBITDA

-4.1M

13M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+42.29 upside

Dividends

By Dow Jones

Next Earnings

27 Feb 2025

Market Stats

By TradingEconomics

Market Cap

2.7B

Previous open

76.76

Previous close

72.03

News Sentiment

By Acuity

88%

12%

371 / 393 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

TransMedics Group Inc Chart

Past performance is not a reliable indicator of future results.

Related News

20 Sept 2024, 03:29 UTC

Top News

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Peer Comparison

Price change

TransMedics Group Inc Forecast

Price Target

By TipRanks

42.29% upside

12 Months Forecast

Average 102.38 USD  42.29%

High 125 USD

Low 75 USD

Based on 9 Wall Street analysts offering 12 month price targets forTransMedics Group Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

71.22 / 72.21Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

371 / 393 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.